Corcept Therapeutics (CORT -5.3%) slips after posting a mixed Q2, reporting an EPS loss that came in better than estimates but missing on its top line revenue number.
Continues to enroll patients in its Phase 3 study of of mifepristone, Korlym's active ingredient, for the treatment of psychotic depression. Results are expected to be released in Q314.
Cash balance as of June 30 was $72.2M, as compared to $93M at December 31, 2012, reflecting approximately $20.8M spent on operations during H113.
Janney Montgomery, Credit Suisse and Ladenbug Thalmann all downgraded the shares to Neutral on the back of the results.
Ladenburg cites a slow Korlym commercial launch and the lack of strong confidence about future commercial prospects as reasons for the downgrade.